{"schema_version":"secwatch.filing_event.v1","accession":"0001559053-24-000003","form_type":"8-K","ticker":"PRTA","cik":"0001559053","company_name":"PROTHENA CORP PUBLIC LTD CO","filed_at":"2024-02-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.603130+00:00","generated_at":"2026-06-06T01:12:41.546631+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Prothena Q4 2023 net loss $67.5M; cash $621M; guides 2024 cash burn ~$208-225M","bullets":["Net loss Q4 $67.5M ($1.26 loss per share) vs net income $6.3M Q4 2022; full year loss $147.0M.","Total revenue Q4 $0.3M (vs $49.9M Q4 2022); full year $91.4M including $55M BMS milestone.","Cash, equivalents & restricted cash $621M at Dec 31, 2023; no debt. 2024 cash use guidance $208-225M.","Phase 1 PRX012 (Alzheimer's) data update expected 2024; partner BMS to advance BMS-986446 to Phase 2 in 1H2024.","AFFIRM-AL birtamimab topline (Mayo Stage IV AL amyloidosis) expected between 4Q2024-2Q2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001559053-24-000003","json":"https://secwatch.observer/filing/0001559053-24-000003.json","markdown":"https://secwatch.observer/filing/0001559053-24-000003.md","text":"https://secwatch.observer/filing/0001559053-24-000003.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1559053/000155905324000003/0001559053-24-000003-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1559053/000155905324000003/prta-20240215.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T01:12:41.546631+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"feb99154ce23968474f67b8fded3beb00a2e8a19","claim":"PROTHENA CORP PUBLIC LTD CO updated its the fourth quarter and fiscal year ended December 31, 2023 guidance (initiated).","evidence_excerpt":"On February 15, 2024, Prothena Corporation plc issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1559053/000155905324000003/0001559053-24-000003-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and fiscal year ended December 31, 2023"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}